EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1 / AKT signaling

Marion Morel iD, Weiwen Long iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Marion Morel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Lung Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer‐related deaths worldwide. Lung adenocarcinomas (LUADs) are a major subtype of non‐small‐cell lung cancers (NSCLCs). About 25% of LUADs harbor GTPase KRAS mutations associated with poor prognosis and limited treatment options. While encouraging tumor response to novel covalent inhibitors specifically targeting KRASG12C has been shown in the clinic, either intrinsic resistance exists or acquired therapeutic resistance arises upon treatment. There is an unmet need to identify new therapeutic targets for treating LUADs with activating KRAS mutations, particularly those with resistance to KRASG12C inhibitor(s). In this study, we have revealed that F‐box/LRR‐repeat protein 16 (FBXL16) is selectively upregulated in LUAD with KRAS mutations. It promotes LUAD cell growth and transforms lung epithelial cells. Importantly, FBXL16 depletion greatly enhances sensitivity to the KRASG12C inhibitor (sotorasib) in resistant cells by downregulating phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (PKB; also known as AKT) signaling. Mechanistically, FBXL16 upregulates insulin receptor substrate 1 (IRS1) protein stability, leading to an increase of IGF1/AKT signaling, thereby promoting cell growth and migration. Taken together, our study highlights the potential of FBXL16 as a therapeutic target for treating LUAD with KRAS activating mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinoma of LungHumansProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Insulin Receptor Substrate ProteinsPhosphatidylinositol 3-KinasesDrug ResistanceMutation

Stichwörter der Autor:innen

AKTFBXL16IRS1KRASlung adenocarcinomaprotein stability

Substanzen

Proto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Insulin Receptor Substrate ProteinsPhosphatidylinositol 3-KinasesIRS1 protein, humanKRAS protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.

ORCID-Profile: Marion Morel, Weiwen Long

Förderung

  • American Lung Association

Zitieren

APA

Morel, M., & Long, W. (2024). FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1 / AKT signaling. Molecular Oncology. https://doi.org/10.1002/1878-0261.13554

Vancouver

Morel M, Long W. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1 / AKT signaling. Molecular Oncology. 2024. doi:10.1002/1878-0261.13554

BibTeX
@article{Morel2024,
  author = {Morel, Marion and Long, Weiwen},
  title = {FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1 / AKT signaling},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13554}
}
Kostenlos starten →